诺诚健华医药有限公司(09969)于2026年7月15日发布翌日披露报表。公告显示，公司在香港联交所上市的普通股数量维持1,493,798,235股不变，库藏股数为2,486,000股。与此同时，公司根据2023年人民币股股份激励计划，于上海证券交易所科创板增发人民币普通股2,044,750股，每股发行价为人民币6.95元。
此次增发涉及向2名董事、1名高级管理人员及多批激励对象共授予2,044,750股人民币普通股，占发行前公司已发行股份(不含库藏股)总数的约0.12%。增发完成后，诺诚健华在科创板上市的人民币普通股由270,778,017股增加至272,822,767股。
公司在公告中确认，本次发行已获得董事会正式授权，并已遵守香港联交所及相关法律法规的要求。公告由主席兼执行董事崔霁松博士签署。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.